Exhibit 99.5

 

 

Dr. Reddy’s Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills

Hyderabad – 500 034, Telangana,

India

CIN: L85195TG1984PLC004507

 

Tel: + 91 40 4900 2900

Fax: + 91 40 4900 2999

Email: mail@drreddys.com

www.drreddys.com

 

May 12, 2026

 

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

 

Dear Sir/Madam,

 

Subject: Decaration under Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

 

Dear Sirs/Madam,

 

Pursuant to the provisions of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, I, M V Narasimham, Chief Financial Officer of the Company hereby declare that, the Statutory Auditors of the Company, M/s. S R Batliboi & Associates LLP, Chartered Accountants (Firm Registration No. 101049W/E300004), have issued an Audit Report with unmodified opinion on the annual Audited Financial Results of the Company (Standalone & Consolidated) for year ended on March 31, 2026.

 

Request you to kindly take this declaration on your records.

 

 

 

M V Narasimham

Chief Financial Officer  

 

Date: 12.05.2026

Place: Hyderabad

 

  

 

   

 

 

 

THE SKYVIEW 10

18th Floor, “NORTH LOBBY”

Survey No. 83/1, Raidurgam

Hyderabad - 500 032, India

 

Tel : +91 40 6141 6000

 

Independent Auditor’s Report on the Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

 

To

The Board of Directors of

Dr. Reddy’s Laboratories Limited

 

Report on the audit of the Standalone Financial Results

 

Opinion

 

We have audited the accompanying “Statement of Audited Standalone Financial Results for the quarter and year ended 31 March 2026” (“Statement”) of Dr. Reddy’s Laboratories Limited (the “Company”), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”).

 

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

 

i.is presented in accordance with the requirements of the Listing Regulations in this regard; and

 

ii.gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net loss and other comprehensive loss and other financial information of the Company for the quarter March 31, 2026 and net profit and other comprehensive loss and other financial information of the Company for the year ended March 31, 2026.

 

Basis for Opinion

 

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended (“the Act”). Our responsibilities under those Standards are further described in the “Auditor’s Responsibilities for the Audit of the Standalone Financial Results” section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

 

Management’s Responsibilities for the Standalone Financial Results

 

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net loss and other comprehensive loss of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

 

 

 

S.R. Batliboi & Associates LLP, a Limited Liability Partnership with LLP Identity No. AAB-4295

Regd. Office : 22, Camac Street, Block ‘B’, 3rd Floor, Kolkata-700 016

 

 

 

 

 

 

In preparing the Statement, the Board of Directors are responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

 

The Board of Directors are also responsible for overseeing the Company’s financial reporting process.

 

Auditor’s Responsibilities for the Audit of the Standalone Financial Results

 

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

 

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

 

·Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
·Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
·Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
·Conclude on the appropriateness of the Board of Directors’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Company to cease to continue as a going concern.
·Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

 

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

 

 

 

 

 

 

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

 

Other Matters

 

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

 

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm Registration Number: 101049W/E300004

 

  

per Shankar Srinivasan

Partner

Membership No.: 213271

 

UDIN: 26213271HWYRVT2241

 

Place: Hyderabad

Date: May 12, 2026

 

 

 

 

 

Dr. Reddy’s Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills,

Hyderabad - 500 034, Telangana,

India.

CIN : L85195TG1984PLC004507

 

Tel     :+91 40 4900 2900

Fax     :+91 40 4900 2999

Email :mail@drreddys.com

www.drreddys.com

 

DR. REDDY’S LABORATORIES LIMITED

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

 

All amounts in Indian Rupees millions

      Quarter ended   Year ended 
      31.03.2026   31.12.2025   31.03.2025   31.03.2026   31.03.2025 
Sl. No.  Particulars  (Audited)   (Unaudited)   (Audited)   (Audited)   (Audited) 
                        
1  Revenue from operations                         
   a) Sales   37,197    40,718    54,063    201,022    218,448 
   b) License fees and service income   829    1,946    1,400    3,584    12,020 
   c) Other operating income   194    163    166    722    686 
   Total revenue from operations   38,220    42,827    55,629    205,328    231,154 
2  Other income   5,672    3,603    4,144    16,896    10,034 
   Total income (1 + 2)   43,892    46,430    59,773    222,224    241,188 
3  Expenses                         
   a) Cost of materials consumed   11,212    10,668    9,426    43,325    37,997 
   b) Purchase of stock-in-trade   4,790    7,692    5,347    26,358    24,399 
   c) Changes in inventories of finished goods, work-in-progress and stock-in-trade   1,162    (1,315)   822    (2,305)   (1,739)
   d) Employee benefits expense   8,345    9,602    7,971    35,499    32,875 
   e) Depreciation and amortisation expense   3,185    3,143    2,645    12,074    10,394 
   f) Impairment of non current assets, net   1,211    157    1,036    1,405    1,036 
   g) Finance costs   543    414    311    1,483    1,099 
   h) Other expenses   16,499    15,027    16,597    61,872    62,768 
   Total expenses   46,947    45,388    44,155    179,711    168,829 
4  Profit/(loss) before tax (1 + 2 - 3)   (3,055)   1,042    15,618    42,513    72,359 
5  Tax expense/(benefit)                         
   a) Current tax   (1,147)   130    3,643    9,177    17,905 
   b) Deferred tax   286    6    (32)   1,139    960 
6  Net profit/(loss) for the period/year (4 - 5)   (2,194)   906    12,007    32,197    53,494 
7  Other comprehensive income                         
   a) (i) Items that will not be reclassified to profit or loss   134    -    (103)   134    (103)
   (ii) Income tax relating to items that will not be reclassified to profit or loss   (34)   -    26    (34)   26 
   b) (i) Items that will be reclassified to profit or loss   (854)   94    1,046    (1,698)   234 
   (ii) Income tax relating to items that will be reclassified to profit or loss   214    (24)   (263)   427    (59)
   Total other comprehensive income/(loss)   (540)   70    706    (1,171)   98 
8  Total comprehensive income/(loss) (6 + 7)   (2,734)   976    12,713    31,026    53,592 
9  Paid-up equity share capital (face value Re. 1/- each)   835    835    834    835    834 
10  Other equity                  312,821    287,732 
11  Earnings per equity share (face value Re. 1/- each)                         
   Basic   (2.63)   1.09    14.41    38.68    64.22 
   Diluted   (2.63)   1.09    14.39    38.64    64.13 
       (Not annualised)    (Not annualised)    (Not annualised)           

 

See accompanying notes to the financial results.

 

  

 

 

 

 

 

DR. REDDY’S LABORATORIES LIMITED

 

Segment information All amounts in Indian Rupees millions

      Quarter ended   Year ended 
      31.03.2026   31.12.2025   31.03.2025   31.03.2026   31.03.2025 
Sl. No.  Particulars  (Audited)   (Unaudited)   (Audited)   (Audited)   (Audited) 
   Segment wise revenue and results                         
1  Segment revenue                         
   a) Global Generics   31,487    38,129    48,287    182,027    204,602 
   b) Pharmaceutical Services and Active Ingredients   8,350    6,257    9,140    29,750    33,904 
   c) Others   130    57    45    464    1,410 
   Total   39,967    44,443    57,472    212,241    239,916 
                             
   Less: Inter-segment revenue   1,747    1,616    1,843    6,913    8,762 
   Total revenue from operations   38,220    42,827    55,629    205,328    231,154 
                             
2  Segment results                         
   Profit/(loss) before tax and interest from each segment                         
   a) Global Generics   (3,141)   2,494    15,231    43,716    69,966 
   b) Pharmaceutical Services and Active Ingredients   67    (794)   256    (883)   353 
   c) Others   147    73    47    494    1,419 
   Total   (2,927)   1,773    15,534    43,327    71,738 
                             
   Less: (i) Finance costs   543    414    311    1,483    1,099 
   (ii) Other un-allocable (income)/expenditure, net   (415)   317    (395)   (669)   (1,720)
   Total profit/(loss) before tax   (3,055)   1,042    15,618    42,513    72,359 

 

Global Generics includes operations of Biologics business. Inter-segment revenue represents sale from Pharmaceutical Services and Active Ingredients to Global Generics at cost.

 

Segmental capital employed

As certain assets of the Company including manufacturing facilities, development facilities and treasury assets and liabilities are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

 

  

 

 

 

 

 

DR. REDDY’S LABORATORIES LIMITED

 

Balance sheet All amounts in Indian Rupees millions
   As at   As at 
   31.03.2026   31.03.2025 
Particulars  (Audited)   (Audited) 
ASSETS          
Non-current assets          
Property, plant and equipment   77,527    58,654 
Capital work-in-progress   13,691    21,564 
Goodwill   853    853 
Other intangible assets   28,921    22,817 
Intangible assets under development   -    404 
Financial assets          
Investments   123,613    103,105 
Loans   5    14 
Other financial assets   2,686    8,562 
Tax assets, net   2,650    1,244 
Other non-current assets   843    662 
Total non-current assets   250,789    217,879 
           
Current assets          
Inventories   49,556    45,758 
Financial assets          
Investments   32,335    28,830 
Trade receivables   41,186    59,590 
Derivative instruments   39    539 
Cash and cash equivalents   3,375    3,197 
Other bank balances   16,201    6,571 
Loans   1,002    - 
Other financial assets   19,351    910 
Other current assets   22,187    19,635 
Total current assets   185,232    165,030 
           
TOTAL ASSETS   436,021    382,909 
           
EQUITY AND LIABILITIES          
Equity          
Equity share capital   835    834 
Other equity   312,821    287,732 
Total Equity   313,656    288,566 
           
Liabilities          
Non-current liabilities          
Financial liabilities          
Lease liabilities   2,501    765 
Provisions   120    54 
Deferred tax liabilities, net   5,899    5,154 
Other non-current liabilities   2,420    1,852 
Total non-current liabilities   10,940    7,825 
           
Current liabilities          
Financial liabilities          
Borrowings   54,190    33,855 
Lease liabilities   679    309 
Trade payables          
Total outstanding dues of micro enterprises and small enterprises   316    210 
Total outstanding dues of creditors other than micro enterprises and small enterprises   18,726    19,721 
Derivative instruments   6,785    1,273 
Other financial liabilities   20,268    19,955 
Other current liabilities   6,320    7,006 
Tax Liabilities, net   1,072    794 
Provisions   3,069    3,395 
Total current liabilities   111,425    86,518 
           
TOTAL EQUITY AND LIABILITIES   436,021    382,909 

 

  

 

 

 

 

 

DR. REDDY’S LABORATORIES LIMITED

 

Statement of cash flows All amounts in Indian Rupees millions
   Year ended   Year ended 
   31.03.2026   31.03.2025 
Particulars  (Audited)   (Audited) 
Cash flows from/(used in) operating activities :          
Profit before tax   42,513    72,359 
Adjustments for:          
Fair value changes and profit on sale of financial instruments measured at FVTPL*, net   (2,052)   (3,128)
Depreciation and amortisation expense   12,074    10,394 
Impairment of non-current assets, net   1,405    1,036 
Allowance for credit losses (on trade receivables and other advances)   175    103 
Loss /(Profit) on sale/disposal of assets, net   (2,074)   428 
Unrealized exchange (gain)/loss, net   (3,117)   (116)
Interest income   (7,771)   (4,825)
Finance costs   1,483    1,099 
Equity settled share-based payment expense   299    382 
Inventories write-down   4,488    2,771 
Changes in operating assets and liabilities:          
Trade receivables   18,278    (13,451)
Inventories   (8,287)   (8,340)
Trade payables   (889)   (517)
Other assets and other liabilities, net   (447)   (81)
Cash generated from operations   56,078    58,114 
Income taxes paid, net   (9,473)   (15,864)
Net cash generated from operating activities   46,605    42,250 
           
Cash flows from/(used in) investing activities :          
Purchase of property, plant and equipment   (20,492)   (23,393)
Proceeds from sale of property, plant and equipment   258    323 
Purchase of other intangible assets   (8,888)   (1,374)
Proceeds from sale of other intangible assets   980    104 
Purchase of investments (including bank deposits)   (41,354)   (22,484)
Proceeds from sale of investments (including bank deposits)   14,968    52,788 
Investments in subsidiary/associates   (5,791)   (67,541)
Interest/dividend income received   3,463    3,998 
Loans and advances given to subsidiaries   (1,050)   (57)
Loans and advances repaid by subsidiaries   59    660 
Net cash used in investing activities   (57,847)   (56,976)
           
Cash flows from/(used in) financing activities :          
Proceeds from issuance of equity shares (including treasury shares)   397    193 
Purchases of treasury shares   -    (1,389)
Proceeds from short-term loans and borrowings, net   20,281    25,840 
Payment of principal portion of lease liabilities   (382)   (281)
Dividend paid   (6,659)   (6,662)
Interest paid   (2,469)   (1,794)
Net cash from financing activities   11,168    15,907 
           
Net increase/(decrease) in cash and cash equivalents   (74)   1,181 
Effect of exchange rate changes on cash and cash equivalents   252    2 
Cash and cash equivalents at the beginning of the year   3,197    2,014 
Cash and cash equivalents at the end of the year   3,375    3,197 

*FVTPL (fair value through profit or loss)

 

  

 

 

 

 

 

DR. REDDY’S LABORATORIES LIMITED

 

Notes:

1 The above statement of audited standalone financial results of Dr. Reddy’s Laboratories Limited (“the Company”), which have been prepared in accordance with the Indian Accounting Standards (’‘Ind AS’’) prescribed under Section 133 of the Companies Act, 2013 (“the Act’’) read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (“SEBI’’) were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 12 May 2026. The Statutory Auditors have issued an unqualified report thereon.
   
2 Revenue from sale of goods for the quarter ended 31 March 2026 includes the consequential impact of reduction in selling price of Lenalidomide product in the United States of USD 50 million. This transaction pertains to the company’s Global Generics segment.
   
3 “License fees and service income” for the year ended 31 March 2025 includes an amount of Rs. 8,113 million (excluding GST) received as a consideration towards transfer of its nutraceutical and vitamins, minerals, herbals, and supplements portfolio to Dr. Reddy’s and Nestlé Health Science Limited (the “Nutraceuticals subsidiary”) as part of the definitive agreement. This transaction pertains to Company’s Global Generics segment.
   
4 During the quarter ended 31 March 2026, the Company has decided to discontinue certain of its R&D programs associated with Chimeric Antigen Receptor T-cell (CAR-T) therapy portfolio in light of current development status and recent clinical trial outcomes. Consequent to this decision, the Company has recognized a net loss of Rs. 1,350 million in the Company’s Global Generics segment, comprising of :
a. Impairment of non-current assets of Rs. 1,135 million (i.e., towards Property, plant and equipment, Intangibles and Right of use assets),
b. Research and development cost reimbursment to subsidiary of Rs.198 million and
c. Other development program related wind down cost of Rs. 17 million.
   
5 “Impairment of non-current assets, net” for the year ended 31 March 2025 primarily includes:
a. an impairment loss of Rs. 862 million (31 March 2024: Rs. 288 million) towards investment in equity shares and preference shares in the subsidiary, Svaas Wellness Limited, consequent to management’s decision to scale down the business operations of certain digital initiatives. This impairment loss pertains to the Company’s Others segment.
b. an impairment loss of Rs. 174 million, consequent to adverse market conditions with respect to certain product related intangibles forming part of the Company’s Global Generics segment.
   
6 “Other income” for the quarter ended 31 March 2026 includes gain on sale of non-current assets, net of Rs. 1,890 million towards divestment of certain product related intangibles i.e., trademarks.
   
7 In respect of the field tax audit report from the Federal Tax Service authority relating to one of its foreign subsidiaries for the period from January 2020 to December 2022, based on its best estimate, the Company had recorded a provision of Rs. 695 million under “Other Expenses” during the three months ended 30 September 2025.

On 23 March 2026, pursuant to the final order from the Federal Tax Service authorities the originally proposed VAT liability was substantially reduced. Based on the final order, an additional provision of Rs. 1,141 million, including applicable interest and penalties, was recognized for the periods covered under audit as well as subsequent period from calendar year 2023 through 31 March 2026.

This additional provision was recorded under “Other Expenses” during the quarter ended 31 March 2026. The Company believes that the likelihood of any further liability on account of this field tax audit is not probable.

This transaction pertains to the Company’s Global Generics segment.
   
8 The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows:
Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code 2020 (collectively referred to as the “New Labour Codes”). The New Labour Codes are effective from 21 November 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations.
 
The Company has assessed the implications of the New Labour Codes and has recognized an incremental cost of Rs.1,101 million towards employee benefits during the year ended 31 March 2026. The Company continues to monitor the developments pertaining to the implementation of the New Labour Codes, including related rules there to and the impact of these will be accounted in accordance with applicable accounting standards.

 

  

 

 

 

 

 

DR. REDDY’S LABORATORIES LIMITED

 

9 The Company received an anonymous complaint in September 2020, alleging that healthcare professionals in Ukraine and potentially in other countries were provided with improper payments by or on behalf of the Company in violation of U.S. anti-corruption laws, specifically the U.S. Foreign Corrupt Practices Act. The Company disclosed the matter to the U.S. Department of Justice (“DOJ”), Securities and Exchange Commission (“SEC”) and Securities Exchange Board of India. The Company engaged a U.S. law firm to conduct the investigation at the instruction of a committee of the Company’s Board of Directors. On 6 July 2021 the Company received a subpoena from the SEC for the production of related documents, which were provided to the SEC.

The Company engaged with the SEC and DOJ, including through submissions and presentations regarding the initial complaint and additional complaints relating to other markets, and in relation to its Global Compliance Framework, which included enhancement initiatives undertaken by the Company, and the Company complied with its listing obligations as it relates to updating the regulatory agencies. On 23 February 2026 the Company received a letter from the SEC stating that, based on the information available to it, the SEC has concluded its investigation and does not intend to recommend any enforcement action against the Company at this time. On 5 March 2026, the Company received a letter from the DOJ stating that, based on the information available to it, the DOJ has closed its inquiry.
   
10 The Company considered the uncertainties relating to geo-political conflicts (including Russia and Ukraine) in assessing the recoverability of receivables, goodwill, intangible assets, investments and other assets. For this purpose, the Company considered internal and external sources of information up to the date of approval of these financial results. Based on its judgments, estimates and assumptions, the Company expects to fully recover the carrying amount of receivables, goodwill, intangible assets, investments and other assets. The Company will continue to closely monitor any material changes to future economic conditions.
   
11 The Board of Directors, at their meeting held on 12 May 2026, have recommended a final dividend of Rs.8 per share subject to the approval of shareholders.
   
12 The figures of the fourth quarter are the balancing figures between audited figures in respect of the full financial year and published year to date figures upto the third quarter of the relevant financial year. Also the figures upto the end of third quarter were only reviewed and not subjected to audit.

  By order of the Board
  For Dr. Reddy’s Laboratories Limited
   
   
Place: Hyderabad G V Prasad
Date: 12 May 2026 Co-Chairman & Managing Director
  DIN: 00057433